Revolution Medicines (RVMD)
187.69
-6.59 (3.39%)
Upcoming Events
Latest Headlines
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
October 21, 2026 4:05 PM - Globe NewsWire
Revolution Medicines starts Phase 3 trial of zoldonrasib for lung cancer
October 20, 2026 8:01 AM - StreetInsider
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastati
October 20, 2026 8:01 AM - Globe NewsWire
Revolution (RVMD) PT Raised to $241 at Truist Securities; 'Longer-Term Thesis Holds Firm'
October 19, 2026 7:19 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Revolution (RVMD)
October 16, 2026 7:54 AM - StreetInsider
Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings
October 16, 2026 6:23 AM - StreetInsider
William Blair Starts Revolution (RVMD) at Outperform
October 16, 2026 2:51 AM - StreetInsider
Revolution Medicines' daraxonrasib gets positive EU panel opinion
October 15, 2026 9:46 AM - StreetInsider
Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
October 15, 2026 9:45 AM - Globe NewsWire
Revolution (RVMD) PT Raised to $260 at RBC Capital
October 14, 2026 8:57 AM - StreetInsider
Form 8-K Revolution Medicines, For: Oct 08
October 13, 2026 4:32 PM - SEC Filing
Revolution (RVMD) PT Raised to $259 at RBC Capital
October 8, 2026 8:27 AM - StreetInsider
Revolution (RVMD) PT Raised to $240 at Truist Securities
October 7, 2026 7:14 AM - StreetInsider
Revolution Medicines starts Phase 3 trial of drug combo for pancreatic cancer
October 5, 2026 8:01 AM - StreetInsider
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
October 5, 2026 8:00 AM - Globe NewsWire
Leerink Resumes Revolution (RVMD) at Outperform
October 5, 2026 6:10 AM - StreetInsider
Form 4 Revolution Medicines, For: Sep 29 Filed by: Sandler Alan B.
October 1, 2026 6:00 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 25 Filed by: Cislini Jeff
September 29, 2026 6:00 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Sandler Alan B.
September 29, 2026 4:25 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 24 Filed by: Mancini Anthony
September 28, 2026 6:00 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 22 Filed by: ANDERSON ELIZABETH M
September 28, 2026 11:55 AM - SEC Filing
Brookline Capital Markets Starts Revolution (RVMD) at Buy
September 28, 2026 7:13 AM - StreetInsider
Form 144 Revolution Medicines, Filed by: Mancini Anthony
September 25, 2026 4:18 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 22 Filed by: ANDERSON ELIZABETH M
September 24, 2026 6:00 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Mancini Anthony
September 24, 2026 4:42 PM - SEC Filing
Goldman Sachs Starts Revolution (RVMD) at Buy
September 24, 2026 5:00 AM - StreetInsider
Form 4 Revolution Medicines, For: Sep 18 Filed by: Mancini Anthony
September 22, 2026 6:00 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: ANDERSON ELIZABETH M
September 22, 2026 4:13 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 16 Filed by: Sandler Alan B.
September 18, 2026 6:06 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 16 Filed by: Mancini Anthony
September 18, 2026 6:05 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 16 Filed by: Kelsey Stephen Michael
September 18, 2026 6:04 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 16 Filed by: Horn Margaret A
September 18, 2026 6:03 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 16 Filed by: GOLDSMITH MARK A
September 18, 2026 6:02 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 16 Filed by: Cislini Jeff
September 18, 2026 6:01 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 16 Filed by: Anders Jack
September 18, 2026 6:00 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Mancini Anthony
September 18, 2026 4:18 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Sandler Alan B.
September 15, 2026 6:11 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Mancini Anthony
September 15, 2026 6:10 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Kelsey Stephen Michael
September 15, 2026 6:09 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Horn Margaret A
September 15, 2026 6:08 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A
September 15, 2026 6:07 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Cislini Jeff
September 15, 2026 6:06 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Anders Jack
September 15, 2026 6:05 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 11 Filed by: Kelsey Stephen Michael
September 15, 2026 6:00 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 10 Filed by: Mancini Anthony
September 14, 2026 6:04 PM - SEC Filing
FDA grants breakthrough therapy status to Revolution Medicines drug for pancreatic cancer
September 14, 2026 4:06 PM - StreetInsider
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
September 14, 2026 4:05 PM - Globe NewsWire
Form 144 Revolution Medicines, Filed by: Kelsey Stephen Michael
September 11, 2026 4:32 PM - SEC Filing
Form 4 Revolution Medicines, For: Sep 08 Filed by: Kim Lorence H.
September 10, 2026 5:53 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Mancini Anthony
September 10, 2026 4:40 PM - SEC Filing
Morgan Stanley Starts Revolution (RVMD) at Overweight
September 10, 2026 3:39 AM - StreetInsider
Revolution (RVMD) PT Raised to $230 at Stifel
September 9, 2026 9:04 AM - StreetInsider
Revolution (RVMD) PT Raised to $275 at Needham
August 31, 2026 7:19 AM - StreetInsider
Revolution (RVMD) PT Raised to $265 at UBS as Daraxonrasib Pricing Announced
August 28, 2026 7:16 AM - StreetInsider
Revolution (RVMD) PT Raised to $275 at Guggenheim
August 28, 2026 7:12 AM - StreetInsider
Revolution (RVMD) PT Raised to $246 at JPMorgan
August 27, 2026 8:30 AM - StreetInsider
Revolution (RVMD) PT Raised to $251 at RBC Capital
August 27, 2026 7:55 AM - StreetInsider
Revolution (RVMD) PT Raised to $280 at H.C. Wainwright
August 27, 2026 7:00 AM - StreetInsider
Revolution (RVMD) PT Raised to $239 at Truist Securities
August 27, 2026 6:59 AM - StreetInsider
Revolution (RVMD) PT Raised to $260 at Oppenheimer
August 26, 2026 5:01 PM - StreetInsider
Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution
August 26, 2026 4:33 PM - PR NewsWire
Revolution Medicines prices RASONQUE at $39,800 per month
August 26, 2026 1:54 PM - StreetInsider
Form 8-K Revolution Medicines, For: Aug 26
August 26, 2026 1:34 PM - SEC Filing
FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
August 26, 2026 12:59 PM - StreetInsider
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
August 26, 2026 12:59 PM - Globe NewsWire
FDA approves Revolution Medicines pancreatic cancer drug Rasonque
August 26, 2026 10:43 AM - StreetInsider
Form 4 Revolution Medicines, For: Aug 21 Filed by: Cislini Jeff
August 25, 2026 4:07 PM - SEC Filing
Form 4 Revolution Medicines, For: Aug 21 Filed by: GOLDSMITH MARK A
August 25, 2026 4:06 PM - SEC Filing
TD Cowen Assumes Revolution (RVMD) at Buy
August 22, 2026 7:54 AM - StreetInsider
Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A
August 21, 2026 4:38 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A
August 21, 2026 4:38 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: GOLDSMITH MARK A
August 21, 2026 4:38 PM - SEC Filing
Form 144 Revolution Medicines, Filed by: Cislini Jeff
August 21, 2026 4:34 PM - SEC Filing
Revolution (RVMD) PT Raised to $179 at Bernstein SocGen Group
August 21, 2026 8:46 AM - StreetInsider
Form SCHEDULE 13G Revolution Medicines, Filed by: BAKER BROS. ADVISORS LP
August 14, 2026 4:03 PM - SEC Filing
Form SCHEDULE 13G/A Revolution Medicines, Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
August 13, 2026 5:20 PM - SEC Filing
Form SCHEDULE 13G Revolution Medicines, Filed by: Janus Henderson Group Ltd.
August 13, 2026 12:31 PM - SEC Filing
Propanc Biopharma plans Phase 1b trial for cancer drug PRP
August 12, 2026 8:32 AM - StreetInsider
Revolution (RVMD) PT Raised to $231 at Truist Securities
August 11, 2026 7:07 AM - StreetInsider
TD Cowen: 'Revolution (RVMD) Firing On All Cylinders'
August 10, 2026 9:09 AM - StreetInsider
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
August 10, 2026 6:00 AM - BizWire
Revolution (RVMD) PT Raised to $230 at Oppenheimer
August 6, 2026 8:37 AM - StreetInsider
Revolution (RVMD) PT Raised to $240 at Needham
August 6, 2026 7:14 AM - StreetInsider
Revolution (RVMD) PT Raised to $203 at RBC Capital
August 6, 2026 6:58 AM - StreetInsider
Revolution (RVMD) PT Raised to $240 at Guggenheim
August 6, 2026 6:45 AM - StreetInsider
Revolution (RVMD) PT Raised to $240 at Wells Fargo
August 6, 2026 6:38 AM - StreetInsider
Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 110c
August 5, 2026 4:54 PM - StreetInsider
Form 10-Q Revolution Medicines, For: Jun 30
August 5, 2026 4:14 PM - SEC Filing
Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 110c
August 5, 2026 4:14 PM - StreetInsider
Form 8-K Revolution Medicines, For: Aug 05
August 5, 2026 4:06 PM - SEC Filing
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
August 5, 2026 4:02 PM - Globe NewsWire
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
July 29, 2026 4:05 PM - Globe NewsWire
Form SCHEDULE 13G Revolution Medicines, Filed by: BlackRock, Inc.
July 29, 2026 3:22 PM - SEC Filing
Full Article List
